Cronos Group (NASDAQ:CRON) and Entia Biosciences (OTCMKTS:ERGO) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.
Risk & Volatility
Cronos Group has a beta of 3.47, meaning that its stock price is 247% more volatile than the S&P 500. Comparatively, Entia Biosciences has a beta of 3.74, meaning that its stock price is 274% more volatile than the S&P 500.
This table compares Cronos Group and Entia Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cronos Group||$12.12 million||415.18||-$14.64 million||($0.08)||-187.13|
|Entia Biosciences||$260,000.00||2.36||-$1.39 million||N/A||N/A|
Entia Biosciences has lower revenue, but higher earnings than Cronos Group.
Insider and Institutional Ownership
8.3% of Cronos Group shares are held by institutional investors. 28.3% of Entia Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Cronos Group and Entia Biosciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cronos Group currently has a consensus target price of $22.49, indicating a potential upside of 50.21%. Given Cronos Group’s higher probable upside, equities research analysts clearly believe Cronos Group is more favorable than Entia Biosciences.
This table compares Cronos Group and Entia Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cronos Group beats Entia Biosciences on 8 of the 11 factors compared between the two stocks.
About Cronos Group
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
About Entia Biosciences
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.